NeoCura and Innovent Announce Strategic Collaboration to Advance Clinical Study of Personalized Neoantigen Vaccine NEO_PLIN2101 in Combination with Sintilimab for Cancer Therapy

October 28, 2021, Shenzhen, China——NeoCura Bio-Medical Technology Co., Ltd. (NeoCura), a biotechnology company dedicated to developing internationally leading AI-enabled innovative RNA therapeutics, andInnovent Biologics Group(HKEX Stock Code: 01801) (Innovent Bio), a biopharmaceutical company dedicated to the research, development, manufacturing, and sales of innovative drugs for the treatment of major diseases such as cancer, metabolic diseases, and autoimmune diseases,jointly announced a strategic partnership to conduct clinical trials evaluating the combination therapy of NeoCura's personalized neoantigen vaccine NEO_PLIN2101 and sintilimab injection for the treatment of tumors.

Under the collaboration agreement, NeoCura and Innovent Bio will establish a clinical research partnership to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination of NeoCura's NEO_PLIN2101 and Innovent Bio's sintilimab in patients with cancer, jointly advance the development of combination immunotherapy for solid tumors, and plan to submit an Investigational New Drug (IND) application to China's National Medical Products Administration (NMPA) in the near future.

NeoCura Founder & CEO Dr. Yi Wangstated: "Neoantigen vaccines currently represent an emerging therapeutic field globally. Since its establishment, NeoCura has been dedicated to the research of tumor neoantigen vaccines, aiming to overcome the challenges of existing immunotherapies in treating solid tumors through the application of novel technologies. We are pleased to enter into this strategic partnership with Innovent Bio. Through this collaboration, we aim to leverage the synergistic effects of personalized neoantigen vaccines and monoclonal antibodies to jointly explore the clinical efficacy of their combined use in solid tumor treatment. This approach is expected to improve the objective response rate of cancer immunotherapy, offering new insights for combination cancer treatment regimens."

Dr. Yongjun Liu, President of Innovent Biologics Groupstated: "We are highly impressed by NeoCura's differentiated R&D pipeline and its international scientific research team. We are delighted to establish this strategic partnership to jointly explore the clinical value of combining sintilimab with neoantigen vaccines for the treatment of solid tumors. Innovent Bio has been deeply committed to the oncology field. We currently have five innovative drugs approved for commercialization in China, with over ten more innovative drugs expected to enter the market in the next two to three years. We have accumulated robust capabilities in pipeline R&D, clinical development, and commercialization, positioning us as an ideal partner for biopharmaceutical peers both domestically and internationally. We also aim to further explore new opportunities presented by combining sintilimab with emerging therapies to expand indications and enhance therapeutic efficacy, and look forward to broader and deeper collaboration with NeoCura in the future."

Through this strategic partnership, both parties will leverage their respective resources and professional strengths to jointly advance the exploration and application of emerging therapies in oncology. This synergistic collaboration is expected to accelerate clinical research in cancer treatment, ultimately benefiting more cancer patients.